Federated Hermes
BOLT icon

Federated Hermes’s Bolt Biotherapeutics BOLT Stock Holding History

Federated Hermes’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-58
Closed -$1.21K – 2058
2023
Q3 		$1.21K Sell
58
-106
-65% -$2.59K ﹤0.01% 2002
2023
Q2 		$4.19K Sell
164
-23
-12% -$730 ﹤0.01% 1917
2023
Q1 		$5.2K Sell
187
-14
-7% -$410 ﹤0.01% 1930
2022
Q4 		$5.24K Buy
201
+94
+88% +$2.58K ﹤0.01% 1924
2022
Q3 		$3K Buy
+107
New +$4.43K ﹤0.01% 1927

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes's BOLT Position: Q4 2023 in Review

Federated Hermes sold out of Bolt Biotherapeutics (BOLT) in Q4 2023, closing a stake of 58 shares — an estimated $1.21K sold.

Federated Hermes first reported a position in BOLT in Q3 2022 and held it in 5 quarters. The position peaked at $5.24K in Q4 2022. 39 funds tracked by Wall St. Rank hold BOLT as of Q4 2023.

  • Federated Hermes reported no remaining Bolt Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Federated Hermes sold 58 Bolt Biotherapeutics shares in Q4 2023, an estimated $1.21K.
  • Federated Hermes first reported a position in Bolt Biotherapeutics in Q3 2022 and held it in 5 quarters.
  • Federated Hermes's Bolt Biotherapeutics position peaked at $5.24K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2023.

Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.